share_log

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

貝爾德維持EyePoint製藥的跑贏大盤,將目標股價下調至38美元
Benzinga ·  05/08 07:02

Baird maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and lowers the price target from $46 to $38.

貝爾德維持EyePoint製藥公司(納斯達克股票代碼:EYPT)的跑贏大盤,並將目標股價從46美元下調至38美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論